H.C. Wainwright raised the firm’s price target on Cogent Biosciences (COGT) to $50 from $21 and keeps a Buy rating on the shares. The firm believes bezuclastinib plus sunitinib is likely to become the standard-of-care in second-line gastrointestinal stromal tumors based on the PEAK trial results.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on COGT:
- Cogent Biosciences Announces Pricing of Public Offerings
- Cogent Biosciences 9.68M share Secondary priced at $31.00
- Cogent Biosciences price target raised to $34 from $14 at Baird
- Cogent announces $200M convertible senior notes, $200M common stock offerings
- Cogent Biosciences: Promising Outlook with Breakthrough GIST Treatment and Strategic Growth Plans